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R E S E A RCH A RTI CLE
Drug-induced block of the cardiac rapid delayed rectifying potassium current (IKr), carried by the human ether-a-go-go-
related gene (hERG) channel, is the most common cause of acquired long QT syndrome. Indeed, some, but not all, drugs that 
block hERG channels cause fatal cardiac arrhythmias. However, there is no clear method to distinguish between drugs that 
cause deadly arrhythmias and those that are clinically safe. Here we propose a mechanism that could explain why certain 
clinically used hERG blockers are less proarrhythmic than others. We demonstrate that several drugs that block hERG 
channels, but have favorable cardiac safety profiles, also evoke another effect; they facilitate the hERG current amplitude 
in response to low-voltage depolarization. To investigate how hERG facilitation impacts cardiac safety, we develop 
computational models of IKr block with and without this facilitation. We constrain the models using data from voltage clamp 
recordings of hERG block and facilitation by nifekalant, a safe class III antiarrhythmic agent. Human ventricular action 
potential simulations demonstrate the ability of nifekalant to suppress ectopic excitations, with or without facilitation. 
Without facilitation, excessive IKr block evokes early afterdepolarizations, which cause lethal arrhythmias. When facilitation 
is introduced, early afterdepolarizations are prevented at the same degree of block. Facilitation appears to prevent early 
afterdepolarizations by increasing IKr during the repolarization phase of action potentials. We empirically test this prediction 
in isolated rabbit ventricular myocytes and find that action potential prolongation with nifekalant is less likely to induce 
early afterdepolarization than action potential prolongation with dofetilide, a hERG channel blocker that does not induce 
facilitation. Our data suggest that hERG channel blockers that induce facilitation increase the repolarization reserve of 
cardiac myocytes, rendering them less likely to trigger lethal ventricular arrhythmias.
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Introduction
A rapid component of the delayed-rectifier potassium current (IKr) 
plays an important role in the repolarization of the cardiac action 
potential (AP). IKr is especially important in ventricular muscle of 
the hearts of large mammals. Certain blockers of IKr are class III 
antiarrhythmic agents, used to treat ventricular tachyarrhythmias 
(Sanguinetti and Jurkiewicz, 1990; Vaughan Williams, 1992; Zeng 
et al., 1995; Clancy et al., 2003). Blockers of IKr prolong the AP dura-
tion (APD) and effective refractory period to suppress premature 
ventricular contraction. Blockade of IKr also is a side effect of many 
drugs. Blockers of IKr can cause acquired long QT syndrome and 
the life-threatening ventricular tachyarrhythmia called “torsades 
de pointes” (Surawicz, 1989; Sanguinetti et al., 1995; Roden, 2000, 
2008; Sanguinetti and Tristani-Firouzi, 2006). At the myocardial 
cellular level, the development of abnormal transient depolariza-
tion during AP repolarization phase called early afterdepolariza-
tion (EAD) has been considered as a trigger of lethal arrhythmias 
related to the usage of IKr blockers (Roden, 2000, 2008; Thomsen 
et al., 2003; Nattel et al., 2007; Weiss et al., 2010). Emphasis on 
detecting IKr blockade early in drug discovery (ICH, 2005) has con-
tributed to the successful removal of torsades de pointes risk for 
new chemical entities. However, there is concern that promising 
new drug candidates are being unnecessarily discarded because 
they benignly block IKr (Sager et al., 2014; Gintant et al., 2016). In-
deed, numerous examples exist of drugs that block IKr and prolong 
the QT interval but have little proarrhythmic risk (De Ponti et al., 
2001; Redfern et al., 2003).
The human ether-a-go-go-related gene (hERG) encodes the 
ion channel through which IKr current passes (Sanguinetti et 
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al., 1995; Trudeau et al., 1995). We have found that some hERG 
blockers also increase hERG currents at potentials close to the 
threshold for channel activation. We refer to this electrical phe-
nomenon as “facilitation” (Hosaka et al., 2007; Furutani et al., 
2011; Yamakawa et al., 2012). A series of hERG blockers with 
lower proarrhythmic risk were found to evoke facilitation of 
hERG (Hosaka et al., 2007; Furutani et al., 2011; Yamakawa et al., 
2012). The correlation between clinical safety and facilitation led 
to our current hypothesis: facilitation by hERG blockers increases 
IKr during cardiac AP repolarization and thereby decreases their 
proarrhythmic risk. Stringently testing this hypothesis requires 
a system in which facilitation can be selectively removed from 
an hERG blocker’s mechanism. In the present study, we test the 
aforementioned facilitation hypothesis by developing a math-
ematical model of the actions of nifekalant, a hERG channel 
blocker that induces facilitation and has been used safely in 
the treatment of life-threatening ventricular tachyarrhythmias 
(Nakaya et al., 1993; Takenaka et al., 2001; Igawa et al., 2002; Sato 
et al., 2017), and calculating the impact of facilitation on the APs 
of human ventricular myocytes.
Materials and methods
Cell preparation and hERG channel current recording
Frogs (Xenopus laevis) were treated in accordance with the 
guidelines for the use of laboratory animals of Osaka University 
Graduate School of Medicine. Isolation and maintenance of the 
oocytes and injection with complementary RNA (cRNA) were 
performed as previously described (Hosaka et al., 2007; Furutani 
et al., 2011; Yamakawa et al., 2012). The hERG expression plasmid 
(provided by Drs. M.T. Keating and M.C. Sanguinetti, University 
of Utah, Salt Lake City, UT; Sanguinetti et al., 1995) was verified 
by sequencing, linearized, and transcribed in vitro using the 
mMES SAGE mMAC HINE Transcription kit (Thermo Fisher Sci-
entific). The oocytes were injected with 5 ng hERG cRNA and in-
cubated at 18°C in ND96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM 
CaCl2, 1 mM MgCl2, and 5 mM HEP ES, pH 7.6 with NaOH) sup-
plemented with 50 µg/ml gentamicin. Membrane currents were 
recorded with the two-electrode voltage-clamp technique with a 
GeneClamp 500 amplifier (Axon Instruments) 4–7 d after cRNA 
injection. The glass electrodes had resistances of 0.4–1.5 MΩ 
when filled with 3 M KCl. Oocytes were bathed in a low-Cl− solu-
tion (96 mM Na-2-(N-morpholino) ethanesulfonic acid [NaMes], 
2 mM KMes, 2 mM CaCl2, 1 mM MgCl2, and 5 mM HEP ES, pH 
7.6 with methane sulfonic acid) to minimize interference from 
endogenous Cl− currents. Oocyte experiments were conducted 
at room temperature (22–25°C).
A human embryonic kidney (HEK) 293 cell line stably ex-
pressing hERG was provided by Dr. C.T. January (University of 
Wisconsin–Madison, Madison, WI) and maintained in minimum 
essential medium supplemented with 10% FBS and 400 µg/ml 
G418 (Axenia Biologix) as previously described (Zhou et al., 
1998). Ventricular myocytes were enzymatically isolated from the 
rabbit ventricles on the day of electrophysiological experiments 
as previously described (Wood et al., 2018). HEK cells or cardiac 
myocytes used for electrophysiological study were adhered to the 
poly-l-lysine–coated (MW 30,000–70,000; Sigma-Aldrich; 0.1 
mg/ml for 2 h at 37°C) coverslips in 12-well plates and transferred 
to a small recording chamber mounted on the stage of an inverted 
microscope (Axiovert S100; Carl Zeiss) and were continuously 
superfused with HEP ES-buffered Tyrode’s solution containing 
(in mM) 137 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 glucose, and 10 
HEP ES, pH 7.4 with NaOH. Membrane currents were recorded 
in a whole-cell configuration established using pipette suction 
(Hamill et al., 1981). Leak compensation was not used. The bo-
rosilicate micropipette had a resistance of 2–4 MΩ when filled 
with the internal pipette solution containing (in mM) 120 KCl, 
5.374 CaCl2, 1.75 MgCl2, 10 EGTA, and 10 HEP ES, pH 7.2 with KOH. 
Liquid junction potential with this internal solution was less than 
−4 mV, and the offset was not corrected. Series resistance was 
typically <5 MΩ. Series resistance compensation was used when 
needed to constrain voltage error to <10 mV. Whole-cell record-
ings were performed using an Axopatch 200B patch-clamp am-
plifier (Molecular Devices), ITC-18 interface, and PatchMaster 
software (HEKA Elektronik). The data were stored on a com-
puter hard disk and analyzed using PatchMaster and Igor Pro 7 
(WaveMetrics). In AP clamp experiments, we used the human 
ventricular AP waveform simulated with our AP model as volt-
age-clamp commands. In AP recordings, ventricular myocytes 
were stimulated with minimal suprathreshold current pulses (2 
ms) at a cycle length of 2,000 ms in whole-cell current clamp 
mode. Beat-to-beat instability of AP was assessed by calculating 
the standard deviation of APD measured at 90% repolarization, 
APD90, based on 30 consecutive beats. EAD was defined as a tran-
sient depolarization during AP phases 2 and 3. Experiments to 
characterize hERG facilitation (Fig. 1; Fig. 2, A–G; Figs. S1, S2, and 
S3) were performed at room temperature (22–25°C), and exper-
iments to test the prediction from simulation studies (Figs. 2 H 
and 11) were performed at 37.0°C, which was maintained with a 
CL-200A temperature controller (Warner Instruments).
Nifekalant was obtained from Nihon Schering and Cayman 
Chemical. Dofetilide was obtained from Alomone Labs. For com-
parisons of dofetilide and nifekalant effects on APs in ventricular 
myocyte, stock solutions were prepared, and then the researcher 
was blinded to their identity during experiments and analysis.
MiRP1 (KCNE2) is a β-subunit of IKr (Abbott et al., 1999). We 
examined whether nifekalant caused distinct effects on cur-
rents mediated by hERG alone and by hERG and KCNE2. Rat 
KCNE2 was provided by Dr. K. Nakajo (Jichi Medical University, 
Shimotsuke City, Japan), subcloned into a mammalian expres-
sion vector, pcDNA3 (Thermo Fisher Scientific), and verified by 
sequencing. Rat KCNE2 was cotransfected with a hERG expres-
sion plasmid and a GFP marker plasmid (pCA-GFP) into HEK293 
cells by using Lipofectamine 2000 reagent (Thermo Fisher Sci-
entific), following the manufacturer’s instructions (typically 
0.5 µg of total DNA/1.5 µl of Lipofectamine 2000 per well in 
12-well plates). Transfected cells were identified by GFP fluo-
rescence and modified hERG gating by KCNE (rightward shift 
in half-activation voltage, V1/2; −10.4 ± 1.5 mV for hERG alone 
vs. −4.2 ± 2.8 mV for hERG with KCNE2; Abbott et al., 1999). We 
found that the drugs caused similar effects on currents from 
hERG + KCNE2 and hERG alone (currents not depicted) and that 
the V1/2 shift due to nifekalant facilitation was similar (Table 1). 
As KCNE2 did not appear to impact the mechanism of facilita-
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tion, we used HEK cells and oocytes expressing hERG channels 
alone for further experiments.
Formulations of kinetic properties for hERG current
To model the macroscopic current of hERG channels expressed 
in HEK293 cells, we first estimated the kinetics of the channels. 
The voltage-dependent activation kinetics (time constant of ac-
tivation) was determined from current activation experiments 
(Fig. 2 A). The activation time constant was measured by fitting 
IKr activation at each depolarized voltage pulse, Vdepo (typically 
Vdepo greater than −40 mV), with a single exponential function:
  I act ( t ) = K [ 1 − exp (− t / τ xr ( V depo ) ] , (1)
where K is the asymptote and τxr(Vdepo) is the activation time con-
stant. Fig. 2 A and Fig. S3 A show the activation time constants 
as a function of Vdepo. Furthermore, the voltage-dependent deac-
tivation kinetics were divided into two processes (i.e., fast and 
slow processes) in accordance with the O’Hara–Rudy formalism 
(O’Hara et al., 2011). From current deactivation experiments (Fig. 
S3 B), the deactivation time constants were measured by fitting 
IKr deactivation at each repolarized voltage pulse, Vrepo (typically 
Vrepo less than −30 mV), to a double exponential function:
  
 I deact ( t ) = K +  A 1 ⋅ exp [ − t / τ xr,fast ( V repo ) ] +    
 A 2 ⋅ exp [ − t / τ xr,slow ( V repo ) ] ,
 (2)
where K is the asymptote, and A1 and A2 are the relative compo-
nents of the fast and slow processes; and τxr,fast and τxr,slow are the 
fast and slow deactivation time constants, respectively. Fig. S3 (C 
and D) shows the fast and slow deactivation time constants as a 
function of Vrepo, respectively. Each time constant value in Eqs. 
1 and 2 was determined by nonlinear least-squares fitting. From 
these experimental data and comparison with kinetics parameters 
of hERG channel in other experiments (Table S1), the activation 
and deactivation time constants were expressed as continuous 
functions of membrane potential, Vm, as follows (Fig. S3, E and F).
For τxr,fast,
  
 τ xr,fast =  
1, 400 ______________  
1 + exp (  V m + 10.0 13.8 ) 
+ 1, 300 ⋅
   
 [ 1 _______________ 1 + exp ( −  V m + 55.0 12.3 ) − 1 ] .
 (3)
For τxr,slow, if Vm ≥ −80 mV,
  
 τ xr,slow =  
5, 000 ______________  
1 + exp (  V m + 22.8 11.5 ) 
+  2, 000 _____________  
1 + exp (  V m + 25 _2.5 ) 
+
    
 4, 000 ______________  
1 + exp ( −  V m + 61.5 5.0 ) 
+  3, 000 ______________  
1 + exp ( −  V m + 54 _2.5 ) 
− 7, 000,
  (4)
and if Vm < −80 mV,
  τ xr,slow = 2, 000 +  
8, 000 _______________  
1 + exp ( −  V m + 74.9 10.2 ) 
. (5)
Modeling of IKr
The IKr current was defined as
  I Kr =  G Kr ⋅  O p ⋅  R Kr ⋅  (   V m −  E K ) , (6)
where GKr is IKr conductance (mS/μF) under the drug action, 
Vm is the membrane potential (mV), EK is the reversal potential, 
Op is the open state variable in the activation of IKr channel, 
and RKr is a time-independent function related to the inactiva-
tion property for IKr. The voltage dependence of the Op in Eq. 
6 was defined as
  O p = f ⋅  x r1 +  ( 1 − f ) ⋅  x r2 , (7)
where xr1 and xr2 are voltage-dependent activation variables for 
unfacilitated and facilitated components in the IKr, respectively, 
and f is a fraction of unfacilitated component in IKr current. The 
dose–fraction relationship of f for nifekalant with an EC50 of 92.84 
nM and a Hill coefficient (he) of 1.50 was represented as follows:
  f =  1 _ 
1 +  (    [ D ]  _  EC 50 ) 
 h e 
 
. (8)
In O’Hara–Rudy dynamic (ORd) model (O’Hara et al., 2011), the 
voltage-dependent activation variable was comprised of two 
variables as follows:
  x ri =  A xr,fast ⋅  x ri,fast +  A xr,slow ⋅  x ri,slow , (9)
where i represents the voltage-dependent type, where the volt-
age-dependent type can be unfacilitated (xr1) or facilitated (xr2) 
activation variables, and Axr,fast and Axr,slow (≡ 1−Axr,fast) are the 
fraction of channels with IKr activation gate undergoing fast and 
slow processes, respectively. The fraction Axr,fast was obtained as 
the following function that best reproduces voltage clamp exper-
imental data (Fig. 2):
  A xr,fast = 0.05 +  0.95 ______________  
1 + exp (  V m + 73.4 16.0 ) 
. (10)
The unfacilitated (xr1) and facilitated (xr2) activation vari-
ables were calculated with the following first-order differ-
ential equation:
  d  x ri,j / dt = Φ ⋅  (   x ri,∞ −  x ri,j ) / τ xr,j , (11)
where xri,∞, for i = 1, 2, is the steady-state value of xri,j, i.e., the 
voltage-dependent activation curve in the hERG channel; τxr,j for 
j = fast, slow, is the time constant for xri,j; and Φ is a temperature 
coefficient as expressed at 3[(T−25)/10], where T is temperature. The 
voltage-dependent activation curve in the hERG channel (xri,∞, 
for i = 1, 2) is well represented by a single Boltzmann function. 
Based on our experimental data (Fig. 2, A and C), we set the Boltz-
mann function’s half-activation voltage (V1/2) and the slope factor 
to –10.7 mV and 7.4, respectively, as the voltage dependence of the 
unfacilitated component (xr1,∞) in IKr activation, and shifted the 
Table 1. Shift of the hERG activation curve by facilitation effect
Cells (n) ΔV1/2 (mV)
HEK293 stably expressing hERG (7) −26.5 ± 1.2
HEK293 transiently expressing hERG (8) −24.9 ± 2.4
HEK293 transiently expressing hERG with KCNE2 (8) −24.4 ± 1.1
Xenopus oocyte transiently expressing hERG (10) −26.6 ± 1.2
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voltage dependence of facilitated components (xr2,∞) in IKr activa-
tion by 26.5 mV in the negative direction (Fig. 2 G), i.e.,
  x r1,∞ =  1 ______________ 
1 + exp ( −  V m + 10.7 7.4 ) 
, (12)
  x r2,∞ =  1 ______________ 
1 + exp ( −  V m + 37.2 7.7 ) 
. (13)
Furthermore, the RKr was reconstructed as the following function 
that best reproduces voltage clamp experimental data (Fig. 2 A):
  
 R Kr =  [ 0.12 +  0.88 ______________  1 + exp (  V m + 60.3 27 ) ] ⋅   
 [ 0.32 +  0.68 ____________  1 + exp (  V m − 7 _20 ) ] .
 (14)
Based on our experimental measurement (Figs. 2 and S4), the GKr 
of when the IKr was blocked by nifekalant in a concentration-de-
pendent manner with an IC50 of 145 nM and a Hill coefficient (hi) 
of 1.15 was represented as follows:
  G Kr =  g Kr ⋅  1 _ 
1 +  ( [D] _  IC 50 ) 
 h i 
 
(15)
where [D] is the drug concentration (nM) and gKr is the IKr chan-
nel conductance absent drug. The gKr was set to 0.058 mS/μF to 
recapitulate the APD of endocardial myocyte represented in the 
ORd model (O’Hara et al., 2011).
In addition, we constructed a conventional block model modi-
fied only in IKr conductance (block without facilitation model) for 
comparison with the block model with facilitation.
Electrophysiological models for AP simulations
Replacing the IKr model in the original ORd model (O’Hara et al., 
2011) into our aforementioned experimental based IKr model, 
we modified the ORd model and constructed three AP models 
(endocardial [ENDO], midmyocardial [MID], and epicardial 
[EPI]) describing cells from ENDO, MID, and EPI layers of the 
ventricular wall according to O’Hara et al. (2011). Scaling fac-
tors for heterogeneous model implementation are summarized 
in Table S2. To evaluate the impact of the IKr facilitation effect 
on the vulnerability for EAD development in patients with heart 
failure, we also constructed a heart failure model. The electrical 
remodeling of cardiomyocytes in failing hearts is characterized 
by decreases in outward ionic currents, including IKr, the slow 
component of the delayed-rectifier potassium current (IKs), and 
Na+-K+ pump current (INaK), as well as an increase in Na+/Ca2+ 
exchanger current (INCX). Based on a previous study (Elshrif et 
al., 2015), we made several modifications of the ORd endocar-
dial myocyte model (see details in Elshrif et al. [2015] and Table 
S3). These modified ORd models (non–heart failure and heart 
failure models) that were constructed in the present study were 
also implemented in an XML-based Physiological Hierarchy 
Markup Language (PHML), which is available as an open-access 
resource (http:// physiodesigner .org/ ; Asai et al., 2013). Details 
on the modified ORd models as non–heart failing (and failing) 
endocardial myocytes with and without facilitation effect can 
referred from PHML models in PH database (https:// phdb .unit 
.oist .jp/ modeldb/ ; ID931 to 936).
For examining effects of facilitation on AP morphology, 
we further used two mathematical models published by ten 
Tusscher and colleagues (ten Tusscher et al., 2004; ten Tusscher 
and Panfilov, 2006; referred to as the TNNP model) representing 
human ventricular myocytes and by Faber and Rudy (2000) (re-
ferred to as the FRd model) representing guinea pig ventricular 
myocytes. The TNNP model was modified based on a previous 
theoretical study (Vandersickel et al., 2014) for enhancing EAD 
development. Furthermore, for the FRd guinea pig model, we 
made a few modifications based on the EPI myocyte model and 
constructed MID and ENDO myocyte models. Parameter modifi-
cations in both TNNP and FRd models are provided in Table S3. 
In both TNNP and FRd models, the facilitated component that the 
voltage-dependence of IKr activation shifted by 26.5 mV in the 
negative direction was added to each AP model.
Simulation protocol and computation
Voltage-clamping simulations for calculating IhERG for each 
clamped voltage pulse with 4-s duration (Fig. 2) were performed 
using a homemade C language program, simulating by the for-
ward Euler method with a 0.01-ms time step. The activation vari-
ables (xri, for i = 1, 2) was set equal to zero as an initial condition.
The simulated AP was calculated by the fourth-order Runge–
Kutta method with double precision numbers. To minimize tran-
sient responses in each simulation, pacing stimuli of threefold 
diastolic threshold and the stimuli were applied repeatedly until 
the AP response observed in all the models reached the stationary 
state. To evaluate the effects of hERG channel blockade on the 
vulnerability of a cardiomyocyte to premature ventricular con-
tractions, additional simulations were performed using the S1–S2 
stimulation protocol: S1 stimuli until the AP converged to a steady 
state were applied at the stimulating frequency of 1 Hz followed 
by an S2 stimulus with various coupling intervals. When the ef-
fects of the hERG channel blocker on APs were examined, the 
stimulating frequency was set to 0.5 Hz for the ORd and TNNP 
models to avoid the stimulus being applied before the complete 
repolarization of the AP. In the FRd model, the stimulating fre-
quency was set to 1 Hz. All simulations were encoded in C/C++ 
and run on an IBM-compatible computer with the Intel ICC com-
piler version 15.0.1. In addition, major AP simulations presented 
in this study can be reproduced by performing their PHML model 
simulations using Flint software (http:// www .physiodesigner 
.org/ simulation/ flint/ ).
Online supplemental material
Fig. S1 shows the concentration dependence of hERG block by 
nifekalant and dofetilide in Xenopus oocytes and HEK293 cells. 
Fig. S2 shows the voltage dependence of induction of hERG facil-
itation. Fig. S3 shows the voltage dependence of activation and 
inactivation time constants of hERG channel. Fig. S4 shows the 
agreement of the concentration dependence of nifekalant-in-
duced hERG block and facilitation in the experiments and sim-
ulations. Fig. S5 shows the impact of facilitation on the APD in 
normal heart. Table S1 shows the time constants of hERG/IKr ac-
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tivation and deactivation. Table S2 shows the scaling factors for 
heterogeneous model implementation in ORd models. Table S3 
shows the modification parameters of the relevant models.
Results
AP voltage stimuli induce facilitation by nifekalant
The degree of facilitation of IKr depends on the dose of hERG 
blocker and the membrane’s history of voltage changes. Facili-
tation by blockers, with the exception of amiodarone derivative 
KB130015 (Gessner et al., 2010), requires a preceding strong de-
polarization as a conditioning stimulus (Carmeliet, 1993; Jiang et 
al., 1999; Hosaka et al., 2007; Furutani et al., 2011; Yamakawa et 
al., 2012). To test whether cardiac APs are sufficient to stimulate 
facilitation, we applied an AP clamp protocol to hERG channels. 
This experiment assessed hERG current at −50 mV, a potential 
near its activation threshold which leaves the majority of chan-
nels closed. To achieve an adequate signal-to-noise ratio, we used 
Xenopus oocytes to express a high density of hERG channels in 
a membrane with minimal endogenous currents. Based on our 
pilot studies in Xenopus oocyte expression system (Figs. S1 and 
S2), we chose 30 µM nifekalant, the concentration close to the 
IC50 (16.6 ± 2.4 µM, n = 5), as the drug concentration to ensure that 
the assessment of the stimulus-dependent increases respond to 
preceding pulses. Xenopus oocytes were kept at ∼18°C until the 
recordings, and in our experience hERG currents, become un-
stable after heating to 37°C. For this reason, we recorded from 
oocytes at room temperature. We first confirmed that a step de-
polarization (+60 mV for 4 s) as a preceding conditioning pulse 
could induce the facilitation effect of nifekalant (Fig. 1). Similar 
to the strong step depolarization, repeated stimulation with a 
human ventricular myocyte waveform at 1 Hz induced facilita-
tion of nifekalant-treated hERG channels (Fig. 1). The facilitation 
effect on hERG current saturated as the number of APs increased, 
indicating that facilitation reached 90% of its steady-state level 
within 20 heartbeats (Fig. 1 C). Without nifekalant, this voltage 
protocol induced little, if any, increase in hERG current (Fig. 1 D). 
The induction of facilitation by cardiac AP stimuli suggests that 
facilitation is potentially physiologically relevant.
Facilitation can be incorporated into cardiac 
electrophysiology modeling
To understand how facilitation could impact cellular electro-
physiology mechanisms specific to human ventricular myocytes, 
we performed calculations with the ORd human ventricular AP 
model (O’Hara et al., 2011). First, we modified the IKr formula in 
the ORd model to reproduce hERG channel block by nifekalant, 
with or without facilitation. The modified IKr formula was first 
constrained by currents recorded from HEK cells expressing 
hERG (Fig. 2, A–C; and Fig. S3). These voltage clamp recordings 
typically required 40–60 min, and our experience conducting ex-
periments at 37°C suggested the whole-cell recording configura-
tion would be more stable at room temperature over these long 
durations. Consequently, electrophysiology on HEK cells was 
conducted at room temperature, and kinetics were corrected post 
hoc for AP modeling at 37°C. Fig. 2 shows the agreement of our 
IKr model with hERG current from HEK cells and its modulation 
by nifekalant. Left panels of Fig. 2 (D and E) show experimental 
hERG currents blocked with 100 nM nifekalant, before (magenta 
traces) and after (green traces) the induction of facilitation effect 
by a conditioning pulse. After the induction of the facilitation 
effect, nifekalant enhanced the current induced by a −30-mV 
pulse (Fig. 2 D), but it still suppressed the current induced by 
a +30-mV pulse (Fig. 2 E). The current enhancement is due to 
a modification of channel activation gating that shifts the volt-
age dependence to more hyperpolarized membrane potentials 
(Hosaka et al., 2007; Furutani et al., 2011). The voltage depen-
dence of the hERG current in the facilitation condition could be 
Figure 1. Cardiac APs induce hERG facilitation with 
nifekalant. (A and B) Representative cell currents from 
hERG channels in Xenopus oocytes evoked by a test 
pulse from holding potential of –90 to –50 mV before 
and after AP stimulation (1 Hz, 20×, AP waveform is the 
same as Fig. 2 H) and a step pulse (+60 mV for 4 s) in 
the presence of 30 µM nifekalant at room temperature. 
(C) AP–facilitation relation. The fraction of facilitation 
induced by repeating APs is normalized to the fraction 
induced by the +60 mV conditioning step pulse. Exper-
imental data are means ± SEM (n = 8–15). The curve fit 
indicates exponential increase in the facilitation frac-
tion by AP stimulation (facilitation = 1.02 − 0.70 ⋅ exp[−
(#APs)/τ), τ = 5.45 ± 0.02]. (D) Requirement of nifekalant 
in the induction of facilitation. Effects of AP stimulation (1 
Hz, 20×, AP waveform) on the increase in the hERG cur-
rent were tested in the absence and presence of 30 µM 
nifekalant in the Xenopus oocytes (n = 7).
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described as the sum of two Boltzmann functions reflecting two 
populations of hERG currents having different activation voltage 
dependences (Furutani et al., 2011). The high-V1/2 fraction of the 
channel population has biophysical characteristics typical for the 
hERG channel, while the low-V1/2 fraction is facilitated. The facil-
itated V1/2 was shifted negative by −26.5 mV (Table 1). This shift 
was consistent with that of hERG channels expressed in Xenopus 
oocytes (Furutani et al., 2011). Thus, the facilitation effect could 
be explained by a fraction of channels opening with a negatively 
shifted activation curve (Fig. 2, F and G). Inclusion of the facili-
tation effect in the IKr model reproduced measurements of hERG 
currents from voltage-step experiments (Fig. 2, D–G), and over a 
range of concentrations (Fig. S4). Thus, modeling facilitation as 
a negative shift in the voltage-dependence of a component of IKr 
predicted the drug-dependent facilitation of IKr.
We corrected the effect of temperature on channel gating by 
the equation QΔT = (Q10)ΔT/10, where Q10 is 10° temperature co-
efficient of 3. This method is imperfect because hERG kinetics 
are differentially sensitive to temperature: activation has a Q10 
of ∼7.5, deactivation has a Q10 of <1.5, and inactivation and re-
covery from inactivation each have a Q10 of ∼4 (Zhou et al., 1998). 
However, the simple assumption of a universal Q10 = 3 appeared 
adequate: in AP clamp experiments and simulations at 37°C, our 
corrected IKr model predicted the effects of nifekalant on hERG 
currents during AP (Fig. 2 H), indicating that the model describes 
the block and facilitation effects of nifekalant sufficiently to 
allow assessment of the impact of facilitation in simulations of 
human ventricular myocyte electrophysiology.
Facilitation selectively increases IKr during late phase-2 and 
phase-3 repolarization of cardiac APs
To understand the role of facilitation in the cardiac AP, we in-
vestigated the influence of facilitation on AP morphology. When 
endocardial APs are evoked with 1-Hz pacing, 100 nM nifeka-
lant prolonged the APD measured at 90% repolarization, APD90 
(334.4 ms, vs. 257.4 ms in the control condition, see Fig. 3 A), 
in agreement with experimental results in human ventricular 
myocytes (Jost et al., 2005). The AP was slightly further pro-
longed in simulations with IKr block without facilitation (342.0 
ms APD90, compare green and magenta traces in Fig. 3 A). In 
Figure 2. Experimental and simulated macroscopic hERG/IKr currents as modified by nifekalant. (A–C) The macroscopic hERG/IKr currents in response 
to voltage-clamp pulses from −80 to +60 mV in 10-mV increments from a holding potential of −80 mV at room temperature; representative traces (A), the 
relationship between membrane voltage and the steady-state current amplitude and membrane voltage (B), and the tail current amplitude (activation curve; 
C). Experimental data are means ± SEM (n = 11). (D–G) Simulated effects of nifekalant on hERG/IKr currents at room temperature condition. The model 
assumes two populations of channels, with or without facilitation effect by nifekalant (100 nM). The V1/2 of activation for the facilitated fraction of channel was 
approximately −31 mV, almost 26 mV negative to that of control channel (see also Materials and methods). (D and E) The macroscopic hERG/IKr currents in 
response to voltage-clamp pulses from −80 to −30 mV (D) or +30 mV (E) at room temperature. (F and G) The relationship between the tail current amplitude 
and membrane voltage before (F) and after (G) the induction of facilitation effect. Experimental data are means ± SEM (n = 5). (H) The macroscopic hERG/IKr 
currents in response to cardiac AP at 37°C. In D–H, black, red, and green solid lines indicate with control, block with facilitation, and conventional block (block 
without facilitation), respectively. Under the condition in the block with facilitation, IKr comprises two fractions of IKr (see also main text), i.e., facilitated and 
unfacilitated fractions of IKr. In G right panel, orange and cyan dashed lines represent the facilitated and unfacilitated fractions of IKr, respectively. Experimental 
data are means ± SEM (n = 6–11).
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the model, 100 nM nifekalant blocks 40% of total IKr at voltages 
>0 mV with or without facilitation (Fig. 2 G). When facilitation 
is implemented in the model, 32% of the hERG channels enter 
a facilitated state such that they produce substantially more 
IKr than control conditions when the potential is between −20 
and −50 mV (Fig. 2 G). There was little difference between the 
voltage-dependent activation variables in the IKr model during 
phase 1 and early phase 2 of the AP (xr1 and xr2 for the unfacili-
tated channels and facilitated channels, respectively), indicat-
ing that IKr behaved similarly (Fig. 3, B and C). This result is 
consistent with Fig. 2 H and expected, because facilitation has 
little impact on hERG current amplitudes at positive voltages 
(Fig. 2, E–G). During late phase-2 and phase-3 repolarization, 
an increase can be seen in IKr (asterisks in Fig. 3, A–C). However, 
in block conditions with or without facilitation, the APs were 
terminated by an increase in the inward-rectifier potassium 
current (IK1)-mediated repolarization current (Fig. 3 D) before 
much prolongation of the AP by facilitation. Thus, in this model 
of a healthy heart under unstressed conditions, only very mini-
mal IKr facilitation is seen in simulations of facilitated IKr during 
late phase-2 and phase-3 repolarization of the AP (Fig. 3 B) be-
cause the facilitation effect of a negative shift in the voltage 
dependence of IKr activation primarily manifests in a narrow 
voltage range (−50 to −30 mV; see Fig. 2 G), and the AP only 
briefly traverses that voltage range.
Facilitation relieves reverse frequency dependence of 
APD prolongation
Class III antiarrhythmic agents are hERG blockers that are 
used clinically to suppress ventricular tachyarrhythmias 
(Sanguinetti and Jurkiewicz, 1990; Vaughan Williams, 1992; 
Sanguinetti and Tristani-Firouzi, 2006). To suppress tach-
yarrhythmias without provoking torsades de pointes, IKr 
block would ideally be use dependent and prolong APD only 
in response to high-frequency stimulation (Surawicz, 1989; 
Hondeghem and Snyders, 1990). Previous studies reported that 
actions of sotalol (Hafner et al., 1988; Hondeghem and Snyders, 
1990) and dofetilide (Tande et al., 1990) trend against this an-
tiarrhythmic ideal by prolonging APDs more at low than high 
frequencies, showing reverse frequency dependence. Notably, 
sotalol and dofetilide are hERG blockers that do not induce fa-
cilitation (Furutani et al., 2011; Yamakawa et al., 2012). Nifeka-
lant also showed reverse frequency dependence, but it was not 
as marked (Nakaya et al., 1993; Cheng et al., 1996; Igawa et al., 
2002). To determine why, we used our model to test the fre-
quency-dependent effects of nifekalant on APD. The left panel 
of Fig. 4 shows changes in the APD90 with 100 nM nifekalant at 
stimulation frequencies from 0.2 to 2 Hz. Without facilitation 
(magenta trace in Fig. 4 A), the prolongation of APD was more 
effective at lower stimulation frequencies, resulting in a reverse 
frequency dependence. When facilitation was included in the 
model, the reverse frequency dependence became slightly 
weaker at low frequencies (green trace in Fig. 4 B). APD90 with 
facilitation was 5.5 ms shorter than without at 2.0 Hz, 7.7 ms 
shorter at 1.0 Hz, and 10.7 ms shorter at 0.2 Hz (Fig. 4 B). This 
suggests facilitation can partially relieve the reverse frequency 
dependence that is a risk factor for torsades de pointes.
IKr facilitation has greater impacts on repolarization in a 
failing heart model
Heart failure patients are at risk for malignant ventricular ar-
rhythmias. Clinical and theoretical data have shown that the APs 
in heart failure patients at slow and modest heart rates are de-
stabilized compared with healthy subjects (Bayer et al., 2010). 
A more recent study indicated that the APs of the heart failure 
models exhibit stronger rate dependence compared with the 
APs of the normal model and can generate EADs and alternans 
at modest pacing rates (Elshrif et al., 2015). These features are 
thought to trigger ventricular arrhythmias (Roden, 2000, 2008; 
Thomsen et al., 2003; Nattel et al., 2007; Weiss et al., 2010). To 
determine whether facilitation might have a more critical im-
pact on failing hearts, we investigated the frequency-dependent 
effects of IKr facilitation on the simulated AP in a heart failure 
Figure 3. Effect of IKr facilitation on cardiac AP. (A–D) Simulated APs in an 
endocardial ventricular myocyte (A), IKr (B), activation state values for unfa-
cilitated (xr1) and facilitated (xr2) fractions of IKr (C), and IK1 during APs with 
100 nM nifekalant (D). Through A to D, black, green, and magenta solid lines 
indicate with control, block with facilitation, and conventional block (block 
without facilitation), respectively. In B and C, orange and cyan dashed lines 
represent the facilitated and unfacilitated fractions of IKr, respectively. Roman 
numerals above A indicate the phases of the AP in the case of with facilitation.
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model (see Materials and methods; Fig. 5; Elshrif et al., 2015). 
APs in the heart failure model were prolonged from the control 
(non–heart failure) model (compare black traces in Fig. 4 B and 
Fig. 5 B) and were further prolonged by IKr blockade. The effect 
of facilitation was more prominent with low frequency pacing of 
the heart failure model, and the reverse frequency dependence 
of APD prolongation was more dramatically attenuated (com-
pare Fig. 4 A and Fig. 5 A) because the delayed repolarization at 
low frequency pacing prolongs the latency before facilitation 
increases the IKr current. APD90 during block with facilitation 
was 16.5 ms shorter than without facilitation at 2.0 Hz, 36.3 ms 
shorter at 1.0 Hz, and 53.0 ms shorter at 0.2 Hz (Fig. 5 B), sug-
gesting that the electrical remodeling in failing myocytes makes 
cellular responses more sensitive to IKr modulation.
IKr facilitation prevents EAD
Excessive AP prolongation by a hERG blocker showing strong 
reverse frequency dependence creates an electrophysiological 
Figure 4. Frequency-dependent effect of nifekalant on APD in non–heart failure model. Increases in simulated APD90 from the control condition in 
normal, non–heart failure model with 100 nM nifekalant (40% IKr block) at each stimulation frequency. Effects of IKr block and facilitation on the APs in normal, 
non–heart failure model at various simulation frequencies with 100 nM nifekalant.
Figure 5. Frequency-dependent effect of nifekalant 
on APD in heart failure model. (A and C) Increases in 
simulated APD90 from the control condition in heart fail-
ure model with 100 nM nifekalant (40% IKr block; A) and 
50% IKr block (C) at each stimulation frequency. (B and 
D) Effects of IKr block and facilitation on the APs in heart 
failure model at various simulation frequencies with 100 
nM nifekalant (40% IKr block; B) and 50% IKr block (D). 
The small “hook” at the beginning of the AP of 2 Hz is the 
repolarization phase of the previous one.
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environment that favors the development of EAD at low stimu-
lating frequencies. Increasing IKr block from 40% to 50% caused 
further APD prolongation (Fig. 5, C and D). Without facilitation, 
the APD was dramatically prolonged with low-frequency pacing 
(magenta trace in Fig. 5 C). We found that in the heart failure 
model paced at 0.2 Hz, EAD appeared at 50% IKr block without fa-
cilitation (magenta traces in Fig. 5 D), and facilitation suppressed 
these EADs (green traces in Fig. 5 D). Although this pacing is un-
physiologically slow, these findings suggest hERG facilitation 
could have a more significant impact on arrhythmogenesis in 
a failing heart.
To determine the range of conditions over which facilitation 
could potentially suppress proarrhythmic effects of hERG block-
ade, we extended analysis in the heart failure model. Fig. 6 (A–C) 
shows examples of steady-state AP trains in several IKr block con-
ditions. Fig. 6 D shows the changes in APD90 as a function of the 
degree of IKr block. Below 40% block, the drug prolonged APD90 
similarly with or without facilitation (Fig. 6, A and D). Without 
facilitation, APs were destabilized when IKr inhibition was >48% 
(§ in Fig. 6 D; APD90 = 890.0 ms), resulting in alternating EADs 
and periodic EADs. In the bottom panel of Fig. 6 D, we plot APD90 
of AP with EAD; alternating EADs (AL, red), and periodic EADs 
(EAD, deep purple) occur at distinct degrees of IKr block. With 
facilitation, EADs did not appear until 57% inhibition of IKr (|| in 
Fig. 6 D; APD90 = 896.4 ms), indicating that IKr facilitation stabi-
lized the AP. Fig. 6 (B and C) shows examples of steady-state AP 
trains with 50% and 55% block of IKr (conditions indicated by † 
and ‡ in Fig. 6 D, bottom), respectively. These results suggest that 
the facilitation of IKr by blockers reduces proarrhythmic side ef-
fects by preventing the development of EADs. In the non–heart 
failure model of an endocardial cell, a similar antiarrhythmic ef-
fect of facilitation was observed with more extreme IKr blockade 
(Fig. 7 top left and Fig. S5).
APs are heterogeneous between different regions of the ven-
tricles (Drouin et al., 1995,; Konarzewska et al., 1995; Näbauer et 
al., 1996; Szabó et al., 2005). To test whether the facilitation ef-
fects are generalizable to models of myocardial cells from other 
layers of the ventricular wall or just an oddity of one model of an 
endocardial cell, we similarly constructed two other AP models 
(MID, EPI) describing cells from midmyocardial and epicardial 
layers (O’Hara et al., 2011). We found that IKr facilitation can pre-
vent EAD development not only in the endocardial cell but also 
in the MID and EPI models (Fig. 7). In addition to the ORd mod-
els, we tested if IKr facilitation prevents EAD development in the 
TNNP human ventricular AP models (ten Tusscher et al., 2004; 
ten Tusscher and Panfilov, 2006) and in the FRd guinea pig ven-
tricular AP model (Faber and Rudy, 2000). These models differ 
in the AP configuration/duration and the vulnerability of the 
regular AP termination to the decrease in IKr. Kinetic parameters 
of the IKr formula of TNNP models and FRd models are different 
from those of our modified ORd models. The differences in the 
ventricular AP models affect the impact of IKr facilitation on AP, 
but IKr facilitation has a similar preventive effect on EAD devel-
opment in each model (Fig. 7). This suggests that prevention of 
EAD development is not an oddity exclusive to any one model and 
may be a general cardiac electrical phenomenon resulting from 
facilitation of IKr by blockers. Next, we studied the ionic mech-
anism by which IKr facilitation prevents EAD development in a 
cardiac myocyte model.
IKr facilitation suppresses reactivation of L-type Ca2+ chan-
nels. In the heart failure model at 55% inhibition of IKr without 
facilitation (magenta lines in Fig. 8, left), the repolarization delay 
caused by IKr reduction augmented the window current in L-type 
Ca2+ channel current (ICaL) during late AP phase 2 with each stim-
ulation (Fig. 8 C, left). As a result, the evoked APs were gradually 
prolonged with each stimulation, leading to further augmenta-
Figure 6. The effect of IKr facilitation on the APD pro-
longation and EAD development by IKr block. (A–C) 
The steady-state AP trains with 40% (A), 50% (B), and 
55% (C) IKr block in heart failure model with and without 
facilitation. (D) Effect of IKr block and facilitation on the 
APD and the development of EADs in heart failure model. 
Green and magenta lines indicate APD90 of AP (without 
EAD) for block with facilitation or block without facili-
tation, respectively. Asterisk, dagger, and double dagger 
indicate the conditions in A–C, respectively. Sections 
and pipes indicate the upper limits of IKr block where APs 
were normally terminated. When EAD was observed, it 
was classified as either alternated EAD or periodic EAD. 
In the bottom panel of D, red and deep purple dots indi-
cate APD90 of AP with EAD for block without facilitation, 
while light and deep green dots indicate APD90 of AP with 
EAD for block with facilitation. Horizontal bars above the 
dots indicate alternated EAD, AL, or periodic EAD, EAD; 
see also main text.
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tion of the ICaL window current (Fig. 8 C, left) and AP prolon-
gation (Fig. 8 B, left). Then, the stagnated repolarization caused 
more reactivation of L-type Ca2+ channels (arrowhead in Fig. 8 C, 
left), enhancing an inward current component of the net ionic 
current (Inet) during late AP phase 2 (Fig. 8 D, left). This caused 
the inward-outward balance of Inet (asterisks in Fig. 8 D, left) that 
temporally interrupted AP repolarization, followed by a second 
rising phase of the AP that led to EAD. This IKr block-induced 
dysfunction eventually converged to a periodic EAD response 
(Fig. 6 C; Fig. 8 A, right column). In contrast, an increase in IKr 
due to facilitation (blue arrow in Fig. 8 E, right) enhanced an out-
ward current component in Inet during late AP phase 2 and phase 
3 (Fig. 8 D, right). This accelerated the membrane repolarization 
and completed the AP repolarization (Fig. 8 B, right). Thus, facil-
itation suppresses EADs by selectively amplifying IKr during late 
phase 2 and phase 3 of APs when the repolarization is in danger 
of stagnating. The facilitated IKr overwhelms the reactivating ICaL, 
preventing EAD.
Modeling suggests that IKr facilitation could 
improve patient safety
Class III antiarrhythmic agents are powerful antiarrhythmics 
used to treat patients with serious ventricular tachycardias in 
spite of their narrow therapeutic index (Tamargo et al., 2015). 
The maximal therapeutic dose of class III antiarrhythmics is gen-
erally limited by proarrhythmic risk of IKr block. At low doses 
with minimal proarrhythmic risk, nifekalant suppresses malig-
nant ventricular tachyarrhythmia (Takenaka et al., 2001) and im-
proves short-term and long-term survival of adult patients with 
ventricular fibrillation/pulseless ventricular tachycardia (Sato et 
al., 2017). In animal models, a torsades de pointes response was 
not detected with the therapeutic dose of nifekalant (Satoh et 
al., 2004), and nifekalant has a broader safety window than IKr 
blockers without facilitation (Sugiyama, 2008; Yamakawa et al., 
2012). To determine whether nifekalant’s favorable safety pro-
file could be related to the facilitation mechanism, we conducted 
simulations of nifekalant’s predicted safety window with and 
without facilitation.
We calculated the “therapeutic” dose of nifekalant that pro-
longs APD90 by 500 ms, an established clinical standard (Igawa et 
al., 2002; Drew et al., 2010). With facilitation, the simulated ther-
apeutic dose was 278.9 nM (68.0% IKr block); without facilitation, 
14% less drug was required, 240.2 nM (64.1% IKr block; Fig. 9). To 
confirm the antiarrhythmic effect of nifekalant at those thera-
peutic doses, we assessed the vulnerability of cardiomyocytes to 
premature excitation. We measured the refractory period of APs 
in the normal, non–heart failure model by calculating the short-
est timing sufficient to produce secondary voltage overshoot by 
a second stimuli (S2 stimuli) after regular pacing (S1-S2 stimu-
lation protocol). The effective refractory periods with nifekalant 
were 216 or 215 ms longer than control, with or without facilita-
tion, respectively (Fig. 9), suggesting that facilitation has little 
impact on effectiveness as a class III antiarrhythmic. We simu-
lated the safety window for nifekalant as the ratio of the dose that 
produces toxicity (EAD) to the therapeutic dose. Without facilita-
tion, EADs occurred at 657.5 nM, 2.74× the calculated therapeutic 
dose (Fig. 10). With facilitation, EADs did not occur until 894.5 
nM, 3.21× the therapeutic dose. Thus, facilitation widens the sim-
ulated safety window for EADs, suggesting that with facilitation 
an IKr blocker can remain an efficacious class III antiarrhythmic 
agent, with an improved safety profile.
Finally, we empirically tested the prediction that nifekalant 
is less likely to induce EAD than a hERG blocker without facilita-
tion effect. Like nifekalant, dofetilide is a hERG channel blocker 
developed as a class III antiarrhythmic agent, but it carries signif-
icant torsades de pointes arrhythmia risk (Jaiswal and Goldbarg, 
Figure 7. The preventive effects of IKr facilitation on 
EAD development in several ventricular AP models. 
Simulated AP responses in the modified ORd human ven-
tricular myocyte AP models, the modified TNNP human 
ventricular myocyte AP models, and the modified FRd 
guinea pig ventricular myocyte AP models of ENDO, MID, 
and EPI cells. APs in ORd and TNNP models were stimu-
lated at 0.5 Hz, while APs in FRd model were stimulated 
at 1 Hz. In each panel, the intensity of IKr block is indi-
cated as % Block. Magenta lines indicate AP responses 
in the IKr block without facilitation, while green lines 
indicate AP responses in the IKr block with facilitation at 
the same degree of IKr block as the overlaid magenta line 
(as an exception, in FRd model of EPI cell, EAD was not 
observed even by complete IKr block).
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2014), especially in patients with congestive heart failure (Torp-
Pedersen et al., 1999; Brendorp et al., 2002). Unlike nifekalant, 
dofetilide does not cause facilitation of hERG channels (Furutani 
et al., 2011). The cellular mechanisms of EADs upon IKr block 
have been extensively studied in isolated rabbit ventricular my-
ocytes (Zhou et al., 1995; Studenik et al., 2001; Xu et al., 2001; 
Choi et al., 2002; Aiba et al., 2005; Xie et al., 2009; Sato et al., 
2010; Maruyama et al., 2011; Zhao et al., 2012), and we chose this 
well-characterized preparation to compare EAD induction by 
nifekalant and dofetilide. We first determined if EADs could be 
induced by dofetilide block. Previous reports indicated that 1 µM 
dofetilide, but not 100 nM, can induce EADs in isolated rabbit 
ventricular myocytes (Xu et al., 2001; Nalos et al., 2012). Consis-
tent with these previous findings, we observed EADs after appli-
cation of 1 µM dofetilide in isolated rabbit ventricular myocytes 
AP stimulated at 0.5 Hz at 37°C. We then determined the dose of 
nifekalant expected to produce a similar degree of IKr block. In 
hERG channels expressed in HEK293 cells and voltage clamped 
at room temperature, the IC50 for nifekalant block (142.6 ± 13.1 
nM, n = 6) was 5.1× higher than that for dofetilide block (27.7 ± 
5.5 nM, n = 6; Fig. S1). For experiments in myocytes, we com-
pared a 10× higher dose, 10 µM nifekalant versus 1 µM dofeti-
lide, to ensure that nifekalant blocked IKr more than dofetilide. 
In experiments where the researcher was blinded as to whether 
dofetilide or nifekalant were applied, we found that 1 µM dofet-
ilide induced alternant EADs in 26% (5 of 19 myocytes) of rabbit 
ventricular myocytes, but 10 µM nifekalant did not induce EADs 
(0 of 19 myocytes; Fig. 11, A and B). When the data from the five 
dofetilide-treated myocytes showing APs with EADs were ex-
cluded from the analysis, the mean APD90 with 10 µM nifekalant 
was 11.5 ms shorter than those with 1 µM dofetilide (Fig. 11, C and 
D). This indicates that dofetilide has a more extreme broadening 
effect on APs than nifekalant, even when EAD does not occur. The 
beat-to-beat instability, which is another indicator of AP desta-
bilization, was similar between nifekalant and dofetilide groups 
(dofetilide APD90 std = 25.6, nifekalant APD90 std = 23.1). These 
Figure 8. Ionic mechanism of EAD development by IKr 
block and the influence of IKr facilitation. (A–E) Sim-
ulated APs and the changes in the membrane potential 
(Vm; A and B), L-type Ca2+ channels current, ICaL (C), the 
net ionic current, Inet (D), and IKr (E) during APs with 55% 
IKr block in heart failure model. Each simulation of block 
(left) and facilitation (right) was started from the same 
initial values. In each panel of B–E, three curves are over-
laid. Thin dashed line, thick dashed line, and solid line 
indicate 6th, 29th, and 31st AP responses after the 55% 
IKr block, respectively, and these APs are marked with 
squares in A. In C, an arrowhead indicates the time point 
of the reactivation of L-type Ca2+ channels, and asterisks 
indicate the time point of the inward-outward balance 
of Inet in 31st AP response in the case without facilita-
tion (magenta solid line; see also main text). In E, the 
increase in the IKr current in the case with facilitation is 
highlighted by two horizontal dashed lines and an arrow.
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findings are consistent with our conclusion that facilitation of 
hERG channels suppresses the EAD developments in ventricular 
myocytes, as predicted by simulation studies.
Discussion
The objective of this study was to examine the influence of the 
facilitation mechanism on electrical activity in cardiomyocytes. 
This mathematical model represents a general view of the role 
that facilitation may play with IKr blockers. We found that IKr fa-
cilitation effects on simulated cardiac APs depended on the AP 
morphology and APD. Facilitation enhances IKr during prolonged 
APs. The repolarizing effect of facilitated IKr is augmented at low 
frequencies and as APD prolongs, thus avoiding repolarization 
reserve impairment and suppressing EAD development. There-
fore, hERG channel blockers with facilitation may offer a safety 
advantage for arrhythmia treatment.
In a previous article (Furutani et al., 2011), we proposed that 
the increase in hERG current by facilitation could result from 
blockers binding to a second site on the channel. In this “two-
site” model, increased current arises from a population of chan-
nels with blocker bound to a facilitation site causing a shift of 
voltage-dependent activation gating to more negative potentials. 
Herein, we used an analytic Hodgkin–Huxley formulation of the 
two-site model to recapitulate nifekalant’s actions on IKr current 
as the sum of facilitated and unfacilitated fractions (see Materials 
and methods). This empirical kinetic description enabled prac-
tical calculations of macroscopic electrical responses (Fig. 2), to 
model how facilitation could impact cellular electrophysiology 
mechanisms specific to human ventricular myocytes.
We do not yet understand how nifekalant increases the ac-
tivity of hERG channels in terms of statistical thermodynamics. 
Facilitation and blockade appear to be inextricably intertwined, 
as all drugs that cause hERG facilitation are pore blockers of the 
channel (Carmeliet, 1993; Jiang et al., 1999; Hosaka et al., 2007; 
Gessner et al., 2010; Furutani et al., 2011; Yamakawa et al., 2012). 
However, certain mutations in hERG’s S6 helix that lines the K+ 
conduction path affect facilitation without affecting block, sug-
gesting that drug–channel interactions within the pore are in-
volved in facilitation (Hosaka et al., 2007). This suggests that the 
coupling between block and facilitation can be altered. Another 
important characteristic of hERG facilitation is that it requires a 
preceding depolarization. The voltage dependence of the devel-
opment of facilitation in the presence of nifekalant was fitted by 
single Boltzmann function with V1/2 of −19.3 ± 0.9 mV and k of 7.4 
± 0.8 (Fig. S2). Such voltage dependence is similar to the voltage 
dependence of hERG activation (Table 1, in Xenopus oocytes at 
room temperature), suggesting the hERG channel opening has 
a role in developing facilitation effect. In the future, we hope to 
develop a more satisfying Markov-chain type model based on Ey-
ring rate theory that captures the microscopic kinetics of binding 
and conformational changes that underlie nifekalant’s actions.
Our conclusions are based on modeling, yet suggest a general 
cardioprotective mechanism. To exert cardioprotective effects in 
vivo, certain conditions are required. First, the concentration of 
the hERG blocker needs to be in a range conducive to facilitation. 
Second, the membrane potential must depolarize sufficiently to 
induce the IKr facilitation effect. We have previously reported 
the concentration- and voltage-dependence relationships be-
Figure 9. The antiarrhythmic effect of IKr facilitation. Simulation of block 
and facilitation effect on the reexcitation by the second stimulation (S2) in the 
ORd model of nonfailing ENDO cell with the prolonged APD90 by 500 ms. AP 
responses to the S2 stimuli applied at the time indicated.
Figure 10. Effect of IKr facilitation on the safety win-
dow of nifekalant. The changes in the membrane poten-
tial (Vm; upper) and IKr (lower) in the presence of various 
concentrations of nifekalant in normal, non–heart failure 
model. The therapeutic dose is set as the concentration 
that prolongs APD90 by 500 ms and effectively sup-
presses the ectopic excitation as shown in Fig. 9. 2.74× 
indicates 2.74 times higher drug concentration compared 
with its therapeutic dose (1×). Green and magenta lines 
indicate IKr block with and without facilitation, respec-
tively. Roman numerals at the bottom indicate the 
phases of the AP with facilitation.
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tween block and facilitation for several drugs in hERG channels 
expressed in Xenopus oocytes (Furutani et al., 2011; Yamakawa 
et al., 2012). In the present study, we evaluated the concentra-
tion dependence of nifekalant on hERG channels expressed in 
HEK293 cells (Fig. S1 and Table 2). As in oocytes, the IC50/EC50 for 
block and facilitation by nifekalant were similar (92.84 ± 7.71 nM 
for facilitation; 142.6 ± 13.1 nM for block; Table 2). However, for 
other class III antiarrhythmic agents, the concentration depen-
dences of block and facilitation are distinct. For example, the EC50 
for IKr facilitation by amiodarone is lower than that for IC50 block 
(Furutani et al., 2011). These data indicate that when these agents 
are administered in the treatment of arrhythmias at concentra-
tions effective for block, they certainly also reach the effective 
concentration for facilitation. Our experimental data show that 
facilitation by nifekalant could be induced by cardiac APs (Fig. 1). 
An important finding of this work is that facilitation had a negli-
gible impact on APs under normal conditions (Fig. 3 and Fig. 4), 
suggesting that facilitation would not greatly affect normal ECGs. 
Our simulation study suggests that facilitation may have a selec-
tive impact during severe repolarization impairment and heart 
failure conditions, leading to a lower risk of arrhythmias.
It is widely accepted that IKr plays an important role in the 
repolarization of the AP (Surawicz, 1989; Sanguinetti and 
Jurkiewicz, 1990; Zeng et al., 1995; Clancy et al., 2003; Sanguinetti 
Figure 11. Rabbit cardiac myocyte APs are more stable in nifekalant than dofetilide. AP responses in the isolated rabbit ventricular myocytes were stim-
ulated by minimal current injection at 0.5 Hz in whole-cell current clamp mode at 37°C. (A and B) After recording of the control responses (black lines), cells 
were treated with either 1 µM dofetilide (pink lines) or 10 µM nifekalant (green line). (A) Representative AP responses without (left) or with (right) EAD in 1 µM 
dofetilide. Of 19 cells treated with 1 µM dofetilide, five cells showed EAD responses (26%). 14 cells showed the prolongation of APD in 1 µM dofetilide but did 
not show EAD responses. (B) Representative AP responses in 10 µM nifekalant. All cells treated with 10 µM nifekalant showed prolongation of APD upon 1 µM 
dofetilide but did not show EAD responses. (C and D) Prolongation of APD and beat-to-beat instability by 1 µM dofetilide and 10 µM nifekalant. Only the data 
from the cells showing AP responses without EAD were included in this analysis (14 cells of 1 µM dofetilide-treated group; 19 cells of 10 µM nifekalant-treated 
group). 30 consecutive APs responses in control and under the treatment of either 1 µM dofetilide or 10 µM nifekalant were recorded, and APD90 of the i+1th 
action potential (APD90i+1) was plotted against APD90 of the one action potential before (ith; APD90i). APD90s were prolonged by treatment with 1 µM dofetilide 
(C) or 10 µM nifekalant (D) compared with control. 1 µM dofetilide prolonged APD90 longer (P = 4.26 × 10−13, Student’s t test) than 10 µM nifekalant. The control 
APD90s were identical between dofetilide- and nifekalant-treated cells (P = 0.58).
Table 2. Effects of nifekalant on hERG channels: Dose–response (n = 9)
Drug effect IC50/EC50 (nM) Hill coefficient
Block 142.6 ± 13.1 1.10
Facilitation 92.8 ± 7.7 1.50
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and Tristani-Firouzi, 2006). The decrease in IKr is believed to be 
associated with EADs, an important cause of lethal ventricular 
arrhythmias in long QT syndrome and heart failure. Experiments 
by Guo et al. (2011) in isolated nonfailing human endocardial ven-
tricular myocytes showed EADs in the presence of the IKr blocker 
dofetilide (0.1 µM, corresponding to ∼85% IKr block; Thomsen 
et al., 2003), which induces torsades de pointes arrhythmias 
(Thomsen et al., 2003). In the present study using the modified 
ORd model, we successfully reproduced the experimental results 
of Guo et al. (2011), as did the original ORd model (O’Hara et al., 
2011). In rabbit ventricular myocytes, we observed EADs with low 
incidence (26%) in the presence of 1 µM dofetilide. Our result is 
qualitatively consistent with a previous study that found 1 µM 
dofetilide induced EADs in a subset (65%) of rabbit ventricular 
myocytes (Nalos et al., 2012). 10 µM nifekalant did not induce 
EAD under these same conditions, consistent with models pre-
dicting that facilitation prevents EADs. In HEK293 cells either 
1 µM dofetilide or 10 µM nifekalant blocks >99% of hERG current 
(Figs. 11 and S1), which suggests only a small fraction of IKr might 
be available to be facilitated. However, these hERG blockers act by 
partitioning into the cell membrane to access cells, and can have 
dramatically different IC50 values in different cell types (e.g., IC50 
for HEK293 cell vs. Xenopus oocytes were 142.6 ± 13.1 vs. 16.6 ± 
2.4 µM for nifekalant, respectively; 27.7 ± 5.5 vs. 441.6 ± 24.8 nM 
for dofetilide, respectively; Fig. S1 and Furutani et al., 2011). hERG 
blockers have been found to be less effective inhibitors of IKr from 
isolated myocytes than hERG block in HEK293 cells. For example, 
E-4031 blocks hERG current in HEK293 cells with an IC50 of 7.7 
nM (Zhou et al., 1998) and blocks IKr from rabbit ventricular my-
ocytes with an IC50 of ∼20 nM (Zhou et al., 1995, 1998).
Reverse frequency–dependent action on APs is a property 
common to class III antiarrhythmic agents (Hafner et al., 1988; 
Hondeghem and Snyders, 1990; Tande et al., 1990; Carmeliet, 
1993; Jurkiewicz and Sanguinetti, 1993; Nakaya et al., 1993; Jiang 
et al., 1999), and the associated proarrhythmic risk limits their 
clinical usefulness (Hondeghem and Snyders, 1990; Okada et al., 
1996). Reverse frequency dependence of IKr block was first ex-
plained by an increase in the slowly activated delayed-rectifier 
K+ current with rapid heart rates (Jurkiewicz and Sanguinetti, 
1993). Drug mechanisms can prolong APD at higher stimula-
tion frequencies to attenuate reverse frequency dependence 
(Hondeghem and Snyders, 1990). For example, some IKr blockers, 
such as vesnarinone, have high affinities to opened and/or inacti-
vated hERG channels and exhibit an accumulation of inhibition at 
higher stimulation frequencies (use-dependent block), reducing 
proarrhythmic risk (Toyama et al., 1997). In our model, IKr block 
is not altered by stimulation frequency. Therefore, the reverse 
frequency dependence may be even less than predicted. Facilita-
tion attenuates reverse frequency dependence by enhancing IKr 
during late phase 2 and phase 3. The effect on reverse frequency 
dependence becomes more prominent at higher concentrations 
of drug. Fig. 4 and Fig. 5 (A and B) show the effects of the modest 
IKr block by 100 nM nifekalant (∼40% IKr block and ∼32% IKr fa-
cilitation). When the drug concentration increased, the effect of 
facilitation was more prominent (Fig. 5, C and D) because of the 
concentration-dependent increase in the facilitated fraction and 
the prolonged phase 2–3 of AP. Under the higher concentrations 
of blocker, EADs and alternans emerged at low frequencies that 
dramatically affect APD (Fig. 5, C and D). These EADs were effec-
tively suppressed by IKr facilitation (Figs. 6, 7, 8, and S5).
Previous studies showed that ICaL reactivation is crucial for the 
development of EADs (Zeng and Rudy, 1995; O’Hara et al., 2011; 
Tsumoto et al., 2017). Prolongation of the time at plateau voltages 
caused by IKr block allows ICaL reactivation (O’Hara et al., 2011). 
The EAD initiation mechanism in the present study is consistent 
with an ICaL reactivation mechanism (Fig. 8). IKr facilitation ac-
celerates the repolarization just before ICaL reactivation (Fig. 8). 
Therefore, the inward-outward balance of Inet during the plateau 
and AP phase 3 is one determinant for the development of EADs. 
Such inward-outward balance of Inet results from the interaction 
of ionic mechanisms underlying the cardiac AP. In addition to an 
increase in IKr by facilitation, these secondary changes may con-
tribute to preventing ICaL reactivation and development of EADs.
Our modeling and experiments indicate that IKr facilitation 
prevents EAD development, which may decrease proarrhythmic 
risk. In considering the clinical and physiological relevance of 
facilitation to class III antiarrhythmic agents, it is important to be 
aware of the limitations of our study. The models only approxi-
mate currents from isolated myocytes. The absolute voltage and 
concentration dependence of facilitation has not yet been deter-
mined with native IKr currents at physiological temperature. Our 
model of IKr facilitation was constrained by hERG currents from 
HEK cells recorded at room temperature, and the effect of tem-
perature was imperfectly corrected. We have not yet examined 
the facilitation effect on native tissues. Additionally, off-target 
effects of blocker may cause further changes, although appre-
ciable cardiac off-target effects of nifekalant have not yet been 
found. The experiments conducted with rabbit myocytes here 
are limited, and are just the beginnings of an in-depth study into 
induction of EADs by drugs with and without facilitation. These 
types of experiments serve as an important empirical test of our 
hypothesis, but ultimately will lack the precision of modeling re-
sults, as we are unlikely to find hERG blockers with and without 
facilitation that otherwise have identical binding and dissoci-
ation properties. Therefore, a combination of cardiac AP mod-
eling and experiment are expected to provide greater insights 
than either alone.
These limitations notwithstanding, this study sheds light on 
the potential impact of facilitation on cardiac safety. As EAD is 
considered to be a trigger of drug-induced ventricular tachy-
cardia and torsades de pointes arrhythmia (Roden, 2000, 2008; 
Thomsen et al., 2003; Nattel et al., 2007; Weiss et al., 2010), fa-
cilitation defines a novel mechanism that could suppress proar-
rhythmic risk and broaden the safety window of hERG blocking 
agents. The facilitation effect may explain the reason many clin-
ically useful drugs, especially class III antiarrhythmic agents, are 
surprisingly safe, despite hERG block and QT interval prolonga-
tion. Meanwhile, a lack of a facilitation effect may explain why 
dofetilide, d-sotalol, atenolol, and terfenadine have a high risk for 
lethal arrhythmia (Furutani et al., 2011; Yamakawa et al., 2012). 
Recent studies have described the general utility of the in silico 
integration of drug effects on multiple cardiac currents to reduce 
false-positive and false-negative classifications based on hERG 
block alone (Mirams et al., 2011; Kramer et al., 2013). More elab-
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orate models incorporating detailed descriptions of ion channel 
modulation and experimental tests will improve future investi-
gations of the mechanisms underlying the proarrhythmic risk of 
class III antiarrhythmic agents.
In conclusion, we propose that hERG blockers with facilitation 
effects have a lower risk for inducing EADs and other triggered 
activities and thus are more suitable to treat arrhythmias. If this 
hypothesis is correct, it suggests that the early assessment of 
cardiotoxicity risk could be improved by using in vitro ion chan-
nel assays that assess facilitation. Such an improvement could 
reduce the likelihood of mistakenly discarding viable drug candi-
dates and speed the progression of safer drugs into clinical trials 
and clinical use.
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